Synapse - Works

Results (22057)

Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)

Meeting Abstract

George, D. J.; Casey, M.; Degtyarev, E.; Lechuga Frean, M. J.; Aimone, P.; Ravaud, A.; Halabi, S.; Motzer, R. J.
Annals of Oncology (2019)

Fulltext@MSK | Save

KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non-small cell lung cancer (NSCLC)

Meeting Abstract

Gutierrez, M.; Lam, W. S.; Hellmann, M. D.; Gubens, M. A.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma

Meeting Abstract

Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)

Meeting Abstract

Friedlander, M. L.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer

Meeting Abstract

Gartrell, B.; Del Priore, G.; Retter, A.; Chen, W. T.; Sokol, G. H.; Vandell, A.; Roach, M.; Scher, H. I.
Annals of Oncology (2019)

Fulltext@MSK | Save

ACCURACY a phase (P) II trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): Preliminary safety and efficacy data

Meeting Abstract

Ferrarotto, R.; Ho, A.; Wirth, L. J.; Muzaffar, J.; Rodriguez, C.; Dekel, E.; Walker, R. M.; Nadri-Shay, C.; Vergara-Silva, A.
Annals of Oncology (2019)

Fulltext@MSK | Save

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)

Meeting Abstract

Drilon, A.; Cho, B. C.; Kim, D. W.; Lee, J.; Lin, J. J.; Zhu, V.; Camidge, R. D.; Stopatschinskaja, S.; Cui, J. J.; Hyman, D. M.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies

Meeting Abstract

Diaz, L. A.; Le, D.; Maio, M.; Ascierto, P. A.; Geva, R.; Motola-Kuba, D.; André, T.; Van Cutsem, E.; Gottfried, M.; Elez, E.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)

Meeting Abstract

de Wit, R.; Kulkarni, G. S.; Uchio, E.; Boormans, J. L.; Roumiguie, M.; Krieger, L. E. M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

Meeting Abstract

Chi, K. N.; Rathkopf, D.; Attard, G.; Smith, M. R.; Efstathiou, E.; Olmos, D.; Small, E. J.; Lee, J. Y.; Sieber, P.; Dunshee, C.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save